{
  "meta": {
    "run_id": "benchmark-valor-in-patients-with-ckd-egfr-20+ff476536",
    "status": "completed",
    "started_at": "2026-01-25T06:08:37Z",
    "completed_at": "2026-01-25T06:19:18Z",
    "duration_seconds": 641
  },

  "trial_config": {
    "trial_id": "VALOR",
    "trial_name": "VALOR Trial",
    "population": "CKD (eGFR 20-59) undergoing coronary angiography",
    "intervention": "iso-osmolar contrast (iodixanol)",
    "comparator": "low-osmolar contrast (ioversol)",
    "outcome": "CIN within 48-72 hours",
    "regulatory_question": "Is iso-osmolar contrast superior to low-osmolar contrast for preventing CIN in CKD patients?",
    "expected_conclusion": "No significant difference overall; signal of benefit in diabetic subgroup requires confirmation",
    "expected_direction": "null",
    "reference": "Rudnick M et al. Circulation. 2008"
  },

  "step1_causal_question": {
    "completed_at": "2026-01-25T06:09:56Z",
    "duration_seconds": 79,
    "question": "Among adults with chronic kidney disease (baseline eGFR 20-59 mL/min/1.73m2) undergoing coronary angiography, what is the causal effect of receiving iso-osmolar iodixanol (vs. low-osmolar ioversol) as the intravascular contrast agent at the procedure on the 48-72 hour risk of contrast-induced nephropathy (CIN)/post-contrast AKI?",
    "pico": {
      "population": "Adults with CKD (eGFR 20-59) undergoing coronary angiography (+/- PCI)",
      "intervention": "Iso-osmolar iodinated contrast: iodixanol",
      "comparator": "Low-osmolar iodinated contrast: ioversol",
      "outcome": "CIN / post-contrast AKI within 48-72 hours (SCr increase >= 0.5 mg/dL or >= 25% from baseline)"
    },
    "time_zero": "Start of index coronary angiography procedure (first intra-arterial contrast injection)"
  },

  "step2a_design_spec": {
    "completed_at": "2026-01-25T06:13:00Z",
    "duration_seconds": 184,
    "version": 2,
    "design_pattern": "Active Comparator New-User (ACNU) with cross-fitted AIPW (SuperLearner)",
    "data_model": "OMOP CDM v5.x",
    "eligibility_criteria": [
      { "id": 1, "criterion": "Age >= 18 at time zero", "type": "include" },
      { "id": 2, "criterion": "Index coronary angiography identifiable", "type": "include" },
      { "id": 3, "criterion": "Baseline eGFR 20-59 mL/min/1.73m2", "type": "include", "lookback": "-7 days" },
      { "id": 4, "criterion": "Not on maintenance dialysis", "type": "exclude", "lookback": "-365 days" },
      { "id": 5, "criterion": "No kidney transplant history", "type": "exclude" },
      { "id": 6, "criterion": "New-user episode (no angiography in prior 180 days)", "type": "include" },
      { "id": 7, "criterion": "Contrast agent is iodixanol or ioversol", "type": "include" }
    ],
    "outcome_definition": {
      "primary": "CIN (classic): SCr increase >= 0.5 mg/dL OR >= 25% from baseline within 48-72h",
      "secondary": ["PC-AKI (guideline): SCr >= 0.3 mg/dL or >= 1.5x baseline", "AKI diagnosis code", "Acute dialysis", "Composite severe outcome"]
    },
    "analysis_plan": {
      "estimator": "Cross-fitted AIPW with SuperLearner",
      "folds": 5,
      "ps_trimming": [0.025, 0.975],
      "effect_measures": ["Risk Difference (ATE)", "Risk Ratio (RR)"]
    }
  },

  "step2b_validation": {
    "completed_at": "2026-01-25T06:17:51Z",
    "iterations": 2,
    "final_status": "VALID",
    "passed_gates": ["Gate 1", "Gate 2", "Gate 3", "Gate 4", "Gate 5", "Gate 6"],
    "issues_resolved": [
      {
        "gate": "Gate 4",
        "severity": "CRITICAL",
        "issue": "Treatment assignment used post-time-zero data",
        "fix": "Redefined time zero to contrast administration time with +/-6h anchor"
      },
      {
        "gate": "Gate 3",
        "severity": "WARNING",
        "issue": "Code lists were placeholders without vocabulary versioning",
        "fix": "Provided concrete OMOP concept_id sets with Athena build date"
      }
    ]
  },

  "step2c_omop_mapping": {
    "completed_at": "2026-01-25T06:17:58Z",
    "terms_mapped": 61,
    "vocabulary_version": "Athena 2025-12-15",
    "key_concepts": {
      "iodixanol": { "concept_id": 19003201, "domain": "Drug", "vocabulary": "RxNorm" },
      "ioversol": { "concept_id": 19069131, "domain": "Drug", "vocabulary": "RxNorm" },
      "coronary_angiography": { "concept_ids": [4142645, 4223020, 4301351, 4180638, 4052536], "domain": "Procedure" },
      "serum_creatinine": { "concept_ids": [3016723, 3020564, 3016724], "domain": "Measurement" },
      "acute_kidney_injury": { "concept_ids": [761083, 197320, 40481064, 4328366, 37116432, 45757442, 37016366], "domain": "Condition" }
    }
  },

  "step3_code": {
    "completed_at": "2026-01-25T06:19:18Z",
    "duration_seconds": 80,
    "language": "python",
    "lines_of_code": 428,
    "key_components": ["Cohort construction", "Eligibility filtering", "PS estimation (LASSO)", "AIPW estimation", "Diagnostics"]
  },

  "results": {
    "cohort": {
      "initial_population": 71743,
      "after_eligibility": 1692,
      "treatment_arms": { "iodixanol": 823, "ioversol": 869 }
    },
    "primary_outcome": {
      "name": "CIN within 48-72 hours",
      "events": { "intervention": 72, "comparator": 81 },
      "rates": { "intervention": 0.0875, "comparator": 0.0932 },
      "risk_difference": { "estimate": -0.0057, "ci_lower": -0.0333, "ci_upper": 0.0219, "p_value": 0.686 },
      "risk_ratio": { "estimate": 0.939, "ci_lower": 0.698, "ci_upper": 1.264 },
      "e_value": 1.25
    },
    "subgroups": [
      { "name": "Diabetes (Yes)", "n": 856, "risk_difference": -0.0312, "p_value": 0.115, "note": "Signal of benefit requires confirmation" },
      { "name": "Diabetes (No)", "n": 836, "risk_difference": 0.0187, "p_value": 0.337 },
      { "name": "eGFR 20-29", "n": 412, "risk_difference": -0.0198, "p_value": 0.526 },
      { "name": "eGFR 30-44", "n": 687, "risk_difference": -0.0089, "p_value": 0.653 },
      { "name": "eGFR 45-59", "n": 593, "risk_difference": 0.0034, "p_value": 0.856 }
    ],
    "diagnostics": {
      "ps_overlap": 0.847,
      "max_smd_after_weighting": 0.024,
      "ess_ratio": 0.90,
      "negative_controls_analyzed": 12
    }
  },

  "conclusion": {
    "finding": "NO SIGNIFICANT DIFFERENCE",
    "summary": "No statistically significant difference in 48-72 hour CIN risk between iodixanol and ioversol in CKD patients undergoing coronary angiography. Signal of potential benefit in diabetic subgroup warrants further investigation.",
    "effect_estimate": "Risk Difference: -0.57% (95% CI: -3.33% to 2.19%), p=0.686",
    "recommendation": "Evidence does not support preferential use of iso-osmolar over low-osmolar contrast for CIN prevention in the general CKD population."
  },

  "conversation": [
    { "role": "user", "content": "I want to emulate the VALOR trial comparing iodixanol vs ioversol for CIN in CKD patients." },
    { "role": "assistant", "content": "I'll design a target trial emulation using OMOP CDM data. The VALOR trial studied CKD patients (eGFR 20-59) undergoing coronary angiography, comparing iso-osmolar iodixanol to low-osmolar ioversol for 48-72 hour CIN risk. I'll set up an Active Comparator New-User design with cross-fitted AIPW." },
    { "role": "user", "content": "The validation found issues with time-zero alignment?" },
    { "role": "assistant", "content": "The initial design defined time zero as the angiography procedure time but looked forward 6 hours to classify contrast exposure. This violated the principle that treatment must be determined AT time zero, not after. I fixed this by redefining time zero as the earliest contrast administration timestamp, with a +/-6h anchor to the procedure for linkage." },
    { "role": "user", "content": "What do the results show?" },
    { "role": "assistant", "content": "The primary analysis found no significant difference: RD = -0.57% (95% CI: -3.33% to 2.19%), p=0.686. This aligns with the original VALOR RCT. The diabetic subgroup shows a trend toward benefit (RD = -3.12%, p=0.115) that requires prospective confirmation. Good PS overlap (0.847) and covariate balance (max SMD 0.024) support valid inference." }
  ]
}
